{
    "eid": "2-s2.0-85138510141",
    "title": "Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor\u2013positive/human epidermal growth factor receptor 2\u2013negative advanced breast cancer: Primary results from PALOMA-4",
    "cover-date": "2022-11-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Cancer Research",
            "@code": "1306",
            "@abbrev": "BIOC"
        }
    ],
    "keywords": [
        "Advanced breast cancer",
        "Asian",
        "Letrozole",
        "Oestrogen receptor\u2013positive",
        "Palbociclib"
    ],
    "authors": [
        "Binghe Xu",
        "Xichun Hu",
        "Wei Li",
        "Tao Sun",
        "Kunwei Shen",
        "Shusen Wang",
        "Ying Cheng",
        "Qingyuan Zhang",
        "Shude Cui",
        "Zhongsheng Tong",
        "Cuizhi Geng",
        "Erwei Song",
        "Chiun Sheng Huang",
        "Virote Sriuranpong",
        "Roger K.C. Ngan",
        "Yee H. Chia",
        "Xinwei Wang",
        "Huadong Zhao"
    ],
    "citedby-count": 9,
    "ref-count": 24,
    "ref-list": [
        "Contrasting epidemiology and clinicopathology of female breast cancer in Asians vs the US population",
        "Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries",
        "NCCN clinical Practice guidelines in Oncology (NCCN Guidelines\u00ae) breast cancer version 4.2021",
        "The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study",
        "Palbociclib and letrozole in advanced breast cancer",
        "Palbociclib in hormone-receptor-positive advanced breast cancer",
        "Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3",
        "Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up",
        "Palbociclib plus letrozole as first-line therapy in postmenopausal Asian women with metastatic breast cancer: results from the phase III, randomized PALOMA-2 study",
        "Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2- advanced breast cancer in Chinese women",
        "PALOMA-3: phase III trial of fulvestrant with or without palbociclib in premenopausal and postmenopausal women with hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative metastatic breast cancer that progressed on prior endocrine therapy \u2013 safety and efficacy in Asian patients",
        "Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients",
        "Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients",
        "Palbociclib plus fulvestrant in Korean patients from PALOMA-3 with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer",
        "MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer: the multinational randomized phase III study",
        "Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial",
        "Palbociclib with letrozole in postmenopausal women with ER+/HER2- advanced breast cancer: hematologic safety analysis of the randomized PALOMA-2 trial",
        "Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for HR+/HER2- advanced breast cancer",
        "Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: updated analysis with up to 5 years of follow-up",
        "Palbociclib in combination with fulvestrant in women with hormone receptor-positive/HER2-negative advanced metastatic breast cancer: detailed safety analysis from a multicenter, randomized, placebo-controlled, phase III study (PALOMA-3)",
        "Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies",
        "Impact of dose reduction on efficacy: implications of exposure-response analysis of palbociclib",
        "CDK4/6 inhibition on glucose and pancreatic beta cell homeostasis in young and aged rats"
    ],
    "affiliation": [
        {
            "affiliation-city": "Changchun",
            "@id": "60122381",
            "affilname": "The First Bethune Hospital of Jilin University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60122381",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Shanghai",
            "@id": "60108904",
            "affilname": "Fudan University Shanghai Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60108904",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Guangzhou",
            "@id": "60082502",
            "affilname": "Sun Yat-Sen University Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60082502",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Changchun",
            "@id": "60082194",
            "affilname": "Jilin Provincial Cancer Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60082194",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Beijing",
            "@id": "60073456",
            "affilname": "Cancer Institute &amp; Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60073456",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Taipei",
            "@id": "60025370",
            "affilname": "National Taiwan University College of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60025370",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Shanghai",
            "@id": "60024452",
            "affilname": "Ruijin Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60024452",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Harbin",
            "@id": "60021615",
            "affilname": "Harbin Medical University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60021615",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Guangzhou",
            "@id": "60021182",
            "affilname": "Sun Yat-Sen University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60021182",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Tianjin",
            "@id": "60017260",
            "affilname": "Tianjin Medical University Cancer Institute &amp; Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60017260",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Shijiazhuang",
            "@id": "60009884",
            "affilname": "Hebei Medical University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009884",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Shenyang",
            "@id": "60008872",
            "affilname": "China Medical University Shenyang",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60008872",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "New York",
            "@id": "60006989",
            "affilname": "Pfizer Inc.",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006989",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Hong Kong",
            "@id": "60006541",
            "affilname": "The University of Hong Kong",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006541",
            "affiliation-country": "Hong Kong"
        },
        {
            "affiliation-city": "Singapore City",
            "@id": "60002481",
            "affilname": "Tan Tock Seng Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002481",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Zhengzhou",
            "@id": "128127093",
            "affilname": "Henan Cancer Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/128127093",
            "affiliation-country": "China"
        }
    ],
    "funding": [
        "Daiichi",
        "Amgen",
        "Pfizer Inc.",
        "AstraZeneca",
        "Novartis",
        "Roche",
        "MSD",
        "Boehringer Ingelheim",
        "Eisai"
    ]
}